Product Pipeline
OUR MEDICINES IN DEVELOPMENT
Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients.
Key Innovative Programs
- Abrocitinib - JAK1 Inhibitor: Atopic Dermatitis
- Bavencio® (avelumab): Non-Small Cell Lung Cancer, Urothelial Cancer (in collaboration w/Merck KGaA)
- Braftovi® (encorafinib) + Mektovi® (binimetinib): BRAF-mutant metastatic Colorectal Cancer, Melanoma, Non-Small Cell Lung Cancer
- Duchenne Muscular Dystrophy Gene Therapy
- fidanacogene elaparvovec (Coagulation Factor IX Gene Therapy): Hemophilia
- giroctocogene fitelparvovec: Hemophilia Gene Therapy
- Ibrance® (palbociclib): High Risk Early Breast Cancer, Early Breast Cancer in Adjuvant Setting, HER2+ Breast Cancer
- Next Generation Pneumococcal Conjugate Prophylactic Vaccine: Invasive and Non-Invasive Pneumococcal Infections
- Prophylactic Vaccine: Clostridioides difficile Infection
- Ritlecitinib - JAK3/TEC Inhibitor: Alopecia Areata, Vitiligo
- Talzenna® (talazoparib): Prostate Cancer
- Tanezumab: Chronic Pain due to Moderate-to-Severe Osteoarthritis, Cancer Pain
- Xeljanz® (tofacitinib): Ankylosing Spondylitis
- Xtandi® (enzalutamide): Metastatic Hormone Sensitive Prostate Cancer, Non-Metastatic High Risk Hormone Sensitive Prostate Cancer
Pipeline Snapshot as of April 28, 2020
- Discovery Projects
- 27Phase 1
- 37Phase 2
- 21Phase 3
- 6Registration
- Total91
| Compound Name | Indication | Phase | Submission Type | Compound Type |
|---|---|---|---|---|
PF-06425090 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: Biopharma Mechanism of Action: Prophylactic Vaccine | Primary clostridioides difficile infection (FAST TRACK) | Phase 3 | New Molecular Entity | Vaccine |
PF-06482077 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: Biopharma Mechanism of Action: Prophylactic Vaccine | Invasive and Non-Invasive Pneumococcal infections (Adult) (BREAKTHROUGH) | Phase 3 | New Molecular Entity | Vaccine |
PF-06760805 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Invasive Group B Streptococcus Infection (maternal) | Phase 2 | New Molecular Entity | Vaccine |
PF-06842433 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Invasive and Non-Invasive Pneumococcal infections (infants and children) | Phase 2 | New Molecular Entity | Vaccine |
PF-06886992 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Serogroups ABCWY Meningococcal Infections (adolescent and young adults) | Phase 2 | New Molecular Entity | Vaccine |
PF-06928316 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Respiratory Syncytial Virus Infection (maternal) | Phase 2 | New Molecular Entity | Vaccine |
PF-07302048 (BNT162) Therapeutic Area: Vaccines Phase:Phase 1 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic mRNA Vaccine | COVID-19 Infection (in partnership with BioNTech)
Project advanced | Phase 1 | New Molecular Entity | Vaccine |
Braftovi (encorafinib) + Erbitux®(cetuximab) Therapeutic Area: Oncology Phase:Registration Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinased inhibitor | 2nd or 3rd Line BRAF-mutant Metastatic Colorectal Cancer (E.U.) | Registration | Product Enhancement | Small Molecule |
Daurismo (glasdegib) Therapeutic Area: Oncology Phase:Registration Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: SMO (smoothened) antagonist | Combo w/low-dose cytarabine (LDAC) for Acute Myeloid Leukemia (E.U.) | Registration | New Molecular Entity | Small Molecule |
PF-06881894, a potential biosimilar to Neulasta® (Pegfilgrastim) Therapeutic Area: Oncology Phase:Registration Compound Type:Biosimilar Business Segment: Biopharma Mechanism of Action: Human Granulocyte Colony Stimulating Factor | Neutropenia in patients undergoing cancer chemotherapy (Biosimilar) (U.S., E.U.) | Registration | Biosimilar | Biosimilar |
Xtandi (enzalutamide) Therapeutic Area: Oncology Phase:Registration Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: Androgen receptor inhibitor | Metastatic Hormone Sensitive Prostate Cancer (E.U.) | Registration | Product Enhancement | Small Molecule |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Registration Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | 1st Line Urothelial Cancer (Biologic) (BREAKTHROUGH - U.S)
Project advanced | Registration | Product Enhancement | Biologic |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | 1st Line Non-Small Cell Lung Cancer (Biologic) | Phase 3 | Product Enhancement | Biologic |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | 1st Line Urothelial Cancer (Biologic) | Phase 3 | Product Enhancement | Biologic |
Daurismo (glasdegib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: SMO (smoothened) antagonist | Combo w/azacytidine in Acute Myeloid Leukemia (ORPHAN - U.S., E.U.) | Phase 3 | Product Enhancement | Small Molecule |
Ibrance (palbociclib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: CDK 4,6 Kinase Inhibitor | High Risk Early Breast Cancer | Phase 3 | Product Enhancement | Small Molecule |
Ibrance (palbociclib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: CDK 4,6 Kinase Inhibitor | Early Breast Cancer in Adjuvant Setting | Phase 3 | Product Enhancement | Small Molecule |
Ibrance (palbociclib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: CDK 4,6 Kinase Inhibitor | ER+/HER2+ Breast Cancer | Phase 3 | Product Enhancement | Small Molecule |
